Jane Street Group LLC cut its holdings in Radius Health Inc (NASDAQ:RDUS) by 21.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,055 shares of the biopharmaceutical company’s stock after selling 2,135 shares during the quarter. Jane Street Group LLC’s holdings in Radius Health were worth $311,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its position in Radius Health by 144.2% during the second quarter. Russell Investments Group Ltd. now owns 12,562 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 7,417 shares during the last quarter. Sei Investments Co. boosted its position in Radius Health by 27.7% during the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 690 shares during the last quarter. Rhumbline Advisers boosted its position in Radius Health by 9.7% during the second quarter. Rhumbline Advisers now owns 42,480 shares of the biopharmaceutical company’s stock worth $1,921,000 after acquiring an additional 3,740 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in Radius Health during the second quarter worth approximately $1,176,000. Finally, SG Americas Securities LLC boosted its position in Radius Health by 22.9% during the second quarter. SG Americas Securities LLC now owns 8,936 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 1,664 shares during the last quarter.

In other Radius Health news, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the purchase, the insider now owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, VP Brent Hatzis-Schoch bought 1,778 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was acquired at an average cost of $28.09 per share, for a total transaction of $49,944.02. Following the purchase, the vice president now owns 2,278 shares in the company, valued at approximately $63,989.02. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 158,578 shares of company stock worth $4,659,916. 15.00% of the stock is currently owned by insiders.

Radius Health Inc (RDUS) opened at $29.61 on Thursday. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health Inc has a one year low of $24.66 and a one year high of $49.16.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the prior year, the company posted ($1.07) earnings per share. research analysts forecast that Radius Health Inc will post -5.57 earnings per share for the current year.

A number of brokerages recently issued reports on RDUS. Maxim Group restated a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. ValuEngine upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Finally, Jefferies Group cut their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $48.00.

TRADEMARK VIOLATION NOTICE: “Jane Street Group LLC Lowers Stake in Radius Health Inc (RDUS)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/jane-street-group-llc-lowers-stake-in-radius-health-inc-rdus/1775695.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.